IN8BIO, Inc.

NASDAQ:INABUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Contact Information

Headquarters

Empire State Building 350 5Th Avenue, Suite 5330NEW YORK, NY, United States 10118

Phone

646-600-6438

Fax

302-655-5049

Executives

Independent Chairman of the Board

Alan Roemer

President, Chief Executive Officer, Director

William Ho

Co-Founder, Executive Vice President, Chief Scientific Officer

Lawrence Lamb

Chief Financial Officer

Patrick Mccall

Chief Operating Officer

Kate Rochlin